PERCEIVED BENEFITS OF TREATMENTS OF ALZHEIMER’S DISEASE AND RELATED DEMENTIAS FOR COST-EFFECTIVENESS ESTIMATES
Faika Zanjani, Madeline McIntyre, Tracey Gendron, Eline van den Broek-Altenburg · 2024
Read PERCEIVED BENEFITS OF TREATMENTS OF ALZHEIMER’S DISEASE AND RELATED DEMENTIAS FOR COST-EFFECTIVENESS ESTIMATES by Faika Zanjani, Madeline McIntyre, Tracey Gendron, Eline van den Broek-Altenburg (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11692495.txt.
Description
Faika Zanjani and co-authors ask what people value in new dementia drugs beyond extra healthy years. Their 2024 study runs 12 focus groups with people at risk of Alzheimer disease and with caregivers. Standard cost studies count only quality-adjusted life years, which may miss much of what families care about.
Hope and the value of having options ranked high with the groups. Cost and side effects mattered, but so did the strain on family life. Many felt lost in a health system they saw as poorly joined up and short on specialists. The authors say cost studies that skip hope under-price these drugs. Access snags may still blunt their worth.
Catalog record
| CREATOR | Faika Zanjani, Madeline McIntyre, Tracey Gendron, Eline van den Broek-Altenburg |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |